Cardiac Sarcoidosis Randomized Trial (NCT03593759)
Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
Who can join: Review the eligibility criteria below.
Location: Yale-New Haven Hospital — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- Yale-New Haven Hospital — New Haven, Connecticut
- Tufts Medical Center — Boston, Massachusetts
- University of Michigan-Michigan Medicine Cardiovascular Center — Ann Arbor, Michigan
- University of Minnesota — Minneota, Minnesota
- Montefiore Medical Center — New York, New York
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- University of Utah — Salt Lake City, Utah
- Virginia Commonwealth University — Richmond, Virginia
- Libin Cardiovascular Institute of Alberta — Calgary, Alberta
- St. Paul's Hospital — Vancouver, British Columbia
- Eastern Health Health Sciences Centre — St. John's, Newfoundland and Labrador
- QE II Health Sciences Centre — Halifax, Nova Scotia
- St. Joseph's Healthcare Centre — Hamilton, Ontario
- London Health Sciences Centre — London, Ontario
- University of Ottawa Heart Institute — Ottawa, Ontario
- Montreal Heart Institute — Montreal, Quebec
- CIUSSS-Hopital du Sacre-Coeur de Montreal — Montreal, Quebec
- Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval — Québec, Quebec
- CIUSSS de l'Estrie - CHUS - Hôpital Fleurimont — Sherbrooke, Quebec
- Hokkaido University — Sapporo, Kita 8, Nishi 5, Kita-Ku
- Chiba University — Chiba,
- University of Fukui — Fukui,
- St. Marrianna University — Kawasaki,
- Nagoya City University — Nagoya,
📞 Contact the Study Coordinator
Phone: (613) 696-7269
Email: dbirnie@ottawaheart.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiac Sarcoidosis
- A Trial of Baricitinib in Patients With Cardiac Sarcoidosis — Palo Alto, California
- Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression — Philadelphia, Pennsylvania
- Cardiac Sarcoidosis Multi-Center Prospective Cohort — Calgary, Alberta
- Repurposing Tilmanocept for Cardiac Sarcoidosis — Durham, North Carolina
- Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS) — Rochester, Minnesota
Explore by condition: All Cardiac Sarcoidosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.